During intercourse, as the man senses he is approaching climax, both partners stop moving and remain still until the mans feelings of ejaculatory inevitability subside, at which point, they are free to resume active intercourse.These techniques appear to work for around half of people, in the short-term studies that had been done as of 2017.: 27

Medications
As of 2019, there are no drugs specifically approved for the treatment of PE. Selective serotonin reuptake inhibitors (SSRIs) are used to treat PE, including fluoxetine, paroxetine, citalopram, escitalopram  or dapoxetine and clomipramine. The opioid tramadol, an atypical oral analgesic is also used. Results have found PDE5 inhibitors to be effective in combination treatment with SSRIs. The full effects of these medications typically emerge after 2-3 weeks, with results indicating about ejaculatory delay varying between 6–20 times greater than before medication. Premature ejaculation can return upon discontinuation, and the side effects of these SSRIs can also include anorgasmia, erectile dysfunction, and diminished libido.Topical anesthetics such as lidocaine and benzocaine that are applied to the tip and shaft of the penis have also been used. They are applied 10–15 minutes before sexual activity and have fewer potential side effects as compared to SSRIs. However, this is sometimes disliked due to the reduction of sensation in the penis as well as for the partner (due to the medication rubbing onto the partner). Surgical treatments
Two different surgeries, both developed in South Korea, are available to permanently treat premature ejaculation: selective dorsal neurectomy (SDN) and glans penis augmentation using a hyaluronan gel.
Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinsons disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.It was approved in the European Union in February 2015, in the United States in March 2017, and in Canada in January 2019. Medical uses
Safinamide is used to treat idiopathic Parkinsons disease as add-on for people taking a stable dose of levodopa (L-dopa) alone or in combination with other Parkinson drugs, to help with "off" episodes when levodopa stops working. Contraindications
Safinamide is contraindicated in people with severe liver impairment, with albinism, retinitis pigmentosa, severe diabetic neuropathy, uveitis and other disorders of the retina. Combination with other monoamine oxidase (MAO) inhibitors and pethidine is also contraindicated.It is not safe for women to take during pregnancy. It is excreted in breast milk and the effects on infants are unknown. Adverse effects
Common adverse events in clinical trials (in more than 1% of people) included nausea, dizziness, tiredness, sleeplessness, orthostatic hypotension (low blood pressure), and headache. There was no significant difference in the occurrence of these effects between safinamide and placebo.In experiments with rats (but not in those with monkeys), retinopathies have been observed. Overdose
Expected overdose effects are hypertension (high blood pressure), orthostatic hypotension, hallucinations, psychomotor agitation, nausea, vomiting, and dyskinesia. In studies, a single person was suspected to have overdosed for a month; symptoms were confusion, drowsiness and mydriasis (dilation of the pupils) and subsided completely after the drug was discontinued. No specific antidote is available.